Table 3 Characteristics of stage II and III patients with mismatch repair (MMR) competent versus MMR deficient tumours.

	MMR competent (n = 452)	MMR deficient (n = 53)	p Value
Age (y)	70.8 (10.7)	69.2 (14.2)	0.3
Sex (n (%))			0.02
Males	267 (59)	19 (36)
Females	185 (41)	34 (64)
Adjuvant 5‐FU chemotherapy (%)	241 (53)	19 (36)	0.02
Vital status (n (%))
Dead	87 (19)	8 (15)	0.4
Recurrence (n (%))	103 (23)	7 (13)	0.4
Survival (days) (95% CI)	940 (910–970)	940 (853–1028)	0.5
Disease free survival (days) (95% CI)	884 (854–915)	970 (897–1042)	0.1

p values were calculated using the log rank value.

MMR, mismatch repair; 5‐FU, 5‐fluorouracil; 95% CI, 95% confidence interval.